These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 36826463)

  • 1. Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence.
    Fung S; Blair HA
    Target Oncol; 2023 Mar; 18(2):287-294. PubMed ID: 36826463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
    Johnston SRD; Toi M; O'Shaughnessy J; Rastogi P; Campone M; Neven P; Huang CS; Huober J; Jaliffe GG; Cicin I; Tolaney SM; Goetz MP; Rugo HS; Senkus E; Testa L; Del Mastro L; Shimizu C; Wei R; Shahir A; Munoz M; San Antonio B; André V; Harbeck N; Martin M;
    Lancet Oncol; 2023 Jan; 24(1):77-90. PubMed ID: 36493792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
    Johnston SRD; Harbeck N; Hegg R; Toi M; Martin M; Shao ZM; Zhang QY; Martinez Rodriguez JL; Campone M; Hamilton E; Sohn J; Guarneri V; Okada M; Boyle F; Neven P; Cortés J; Huober J; Wardley A; Tolaney SM; Cicin I; Smith IC; Frenzel M; Headley D; Wei R; San Antonio B; Hulstijn M; Cox J; O'Shaughnessy J; Rastogi P;
    J Clin Oncol; 2020 Dec; 38(34):3987-3998. PubMed ID: 32954927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
    Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Harbeck N; Rastogi P; Martin M; Tolaney SM; Shao ZM; Fasching PA; Huang CS; Jaliffe GG; Tryakin A; Goetz MP; Rugo HS; Senkus E; Testa L; Andersson M; Tamura K; Del Mastro L; Steger GG; Kreipe H; Hegg R; Sohn J; Guarneri V; Cortés J; Hamilton E; André V; Wei R; Barriga S; Sherwood S; Forrester T; Munoz M; Shahir A; San Antonio B; Nabinger SC; Toi M; Johnston SRD; O'Shaughnessy J;
    Ann Oncol; 2021 Dec; 32(12):1571-1581. PubMed ID: 34656740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abemaciclib as adjuvant treatment for high-risk early breast cancer.
    Ganfornina Andrades A; Fénix Caballero S; Salguero Olid A; Alegre Del-Rey Emilio J
    Farm Hosp; 2024; 48(2):75-78. PubMed ID: 37735004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abemaciclib as adjuvant treatment for high-risk early breast cancer.
    Ganfornina Andrades A; Fénix Caballero S; Salguero Olid A; Alegre Del-Rey EJ
    Farm Hosp; 2024; 48(2):T75-T78. PubMed ID: 38114413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
    Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A
    J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
    Goetz MP; Martin M; Tokunaga E; Park IH; Huober J; Toi M; Stoffregen C; Shekarriz S; Andre V; Gainford MC; Price GL; Johnston S
    Oncologist; 2020 Sep; 25(9):e1346-e1354. PubMed ID: 32536013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
    Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
    Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
    Rugo HS; O'Shaughnessy J; Boyle F; Toi M; Broom R; Blancas I; Gumus M; Yamashita T; Im YH; Rastogi P; Zagouri F; Song C; Campone M; San Antonio B; Shahir A; Hulstijn M; Brown J; Zimmermann A; Wei R; Johnston SRD; Reinisch M; Tolaney SM;
    Ann Oncol; 2022 Jun; 33(6):616-627. PubMed ID: 35337972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer.
    Sammons S; Moore H; Cushman J; Hamilton E
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):805-814. PubMed ID: 35737886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer].
    Masuda N; Saji S; Kawaguchi T; Chen Y; Ohno S
    Gan To Kagaku Ryoho; 2021 Dec; 48(12):1475-1483. PubMed ID: 34911915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer.
    Royce M; Osgood C; Mulkey F; Bloomquist E; Pierce WF; Roy A; Kalavar S; Ghosh S; Philip R; Rizvi F; Mixter BD; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
    J Clin Oncol; 2022 Apr; 40(11):1155-1162. PubMed ID: 35084948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
    Kaufman PA; Toi M; Neven P; Sohn J; Grischke EM; Andre V; Stoffregen C; Shekarriz S; Price GL; Carter GC; Sledge GW
    Oncologist; 2020 Feb; 25(2):e243-e251. PubMed ID: 32043763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Orozco Leal G; Armstrong N; Kernohan A; Ahmadu C; Coughlan D; McDermott K; Duffy S; O'Meara S; Robinson T; Vale L; Kleijnen J
    Pharmacoeconomics; 2023 Jul; 41(7):741-750. PubMed ID: 36952138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
    Goetz MP; Toi M; Campone M; Sohn J; Paluch-Shimon S; Huober J; Park IH; Trédan O; Chen SC; Manso L; Freedman OC; Garnica Jaliffe G; Forrester T; Frenzel M; Barriga S; Smith IC; Bourayou N; Di Leo A
    J Clin Oncol; 2017 Nov; 35(32):3638-3646. PubMed ID: 28968163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
    Martin M; Hegg R; Kim SB; Schenker M; Grecea D; Garcia-Saenz JA; Papazisis K; Ouyang Q; Lacko A; Oksuzoglu B; Reeves J; Okera M; Testa L; Shimizu C; Denduluri N; Adamchuk H; Dakhil S; Wei R; Forrester T; Fernandez MM; Zimmermann A; Headley D; Johnston SRD
    JAMA Oncol; 2022 Aug; 8(8):1190-1194. PubMed ID: 35653145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
    Paluch-Shimon S; Neven P; Huober J; Cicin I; Goetz MP; Shimizu C; Huang CS; Lueck HJ; Beith J; Tokunaga E; Contreras JR; de Sant'Ana RO; Wei R; Shahir A; Nabinger SC; Forrester T; Johnston SRD; Harbeck N
    Ther Adv Med Oncol; 2023; 15():17588359231151840. PubMed ID: 36756142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.